Lymphoblastic Leukemia Acute
13
0
0
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
23.1%
3 terminated out of 13 trials
66.7%
-19.8% vs benchmark
23%
3 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
A Study of PD5K3 in Healthy Adult Volunteers
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
Treatment of Adult Ph+ LAL With BMS-354825
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)